We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIEV
126
DELISTED
Thunder Power Holdings, Inc. Common Stock
AIEV
$163K 0.04%
15,000
– –
ABT icon
127
Abbott
ABT
$187B
$159K 0.04%
+1,400
New +$160K
NVEI
128
DELISTED
Nuvei Corporation Subordinate Voting Shares
NVEI
$158K 0.04%
+5,000
New +$126K
SRPT icon
129
CALL
Sarepta Therapeutics
SRPT
$1.77B
$155K 0.04%
+1,200
New +$147K
BKHAU
130
Black Hawk Acquisition Corp Units
BKHAU
$85.5M
$152K 0.03%
+15,000
New +$152K
CABA icon
131
Cabaletta Bio
CABA
$455M
$152K 0.03%
+8,900
New +$191K
MLTX icon
132
MoonLake Immunotherapeutics
MLTX
$1.55B
$151K 0.03%
+3,000
New +$163K
PRTA icon
133
Prothena Corp
PRTA
$450M
$148K 0.03%
5,988
-114
-2% -$3.39K
PCVX icon
134
Vaxcyte
PCVX
$8.64B
$137K 0.03%
2,000
+1,900
+1,900% +$132K
MCK icon
135
McKesson
MCK
$101B
$134K 0.03%
+250
New +$127K
GHRS icon
136
GH Research
GHRS
$2.08B
$134K 0.03%
+12,583
New +$99.9K
AVTX icon
137
Avalo Therapeutics
AVTX
$983M
$131K 0.03%
+6,000
New +$32.3K
IONS icon
138
Ionis Pharmaceuticals
IONS
$9.4B
$126K 0.03%
+2,900
New +$138K
TSHA icon
139
Taysha Gene Therapies
TSHA
$1.89B
$125K 0.03%
43,500
-165,500
-79% -$345K
FBRX icon
140
Forte Biosciences
FBRX
$1.57B
$119K 0.03%
+6,820
New +$119K
KALV
141
DELISTED
KalVista Pharmaceuticals
KALV
$119K 0.03%
+10,000
New +$133K
EXAS
142
DELISTED
Exact Sciences
EXAS
$117K 0.03%
+1,700
New +$108K
OGN icon
143
Organon & Co
OGN
$3.57B
$113K 0.03%
+6,000
New +$103K
AMLX icon
144
Amylyx Pharmaceuticals
AMLX
$2.54B
$110K 0.03%
38,858
-38,700
-50% -$506K
JD icon
145
JD.com
JD
$44.5B
$110K 0.02%
+4,000
New +$97.9K
BHVN icon
146
CALL
Biohaven
BHVN
$2.21B
$109K 0.02%
+2,000
New +$99K
FORL
147
DELISTED
Four Leaf Acquisition Corp
FORL
$107K 0.02%
10,000
– –
GPCR icon
148
Structure Therapeutics
GPCR
$3.78B
$107K 0.02%
2,500
-1,500
-38% -$63.3K
SLRN
149
DELISTED
ACELYRIN
SLRN
$101K 0.02%
15,021
+8,021
+115% +$60.9K
LBPH
150
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$98.9K 0.02%
4,580
+3,780
+473% +$82.4K
4 5
6
7 8

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.